| Basics |
Summit Therapeutics Inc. Common Stock
Summit Therapeutics PLC is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies.
|
| IPO Date: |
April 1, 2015 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$18.09B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.27 | 3.86%
|
| Avg Daily Range (30 D): |
$0.70 | 2.98%
|
| Avg Daily Range (90 D): |
$1.02 | 4.34%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.89M |
| Avg Daily Volume (30 D): |
2.97M |
| Avg Daily Volume (90 D): |
3.84M |
| Trade Size |
| Avg Trade Size (Sh.): |
148 |
| Avg Trade Size (Sh.) (30 D): |
89 |
| Avg Trade Size (Sh.) (90 D): |
89 |
| Institutional Trades |
| Total Inst.Trades: |
1,041 |
| Avg Inst. Trade: |
$2.78M |
| Avg Inst. Trade (30 D): |
$4.71M |
| Avg Inst. Trade (90 D): |
$3.21M |
| Avg Inst. Trade Volume: |
.21M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$5.02M |
| Avg Closing Trade (30 D): |
$11.19M |
| Avg Closing Trade (90 D): |
$8.22M |
| Avg Closing Volume: |
389.32K |
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q4 2024 |
|
Basic EPS
|
$-.35
|
$-.09
|
$-.09
|
|
Diluted EPS
|
$-.35
|
$-.09
|
$-.09
|
|
Revenue
|
$
|
$
|
$ .21M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -240.76M
|
$ -62.91M
|
$ -61.2M
|
|
Operating Income / Loss
|
$
|
$
|
$ -65.61M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ 150.18M
|
$ 106.62M
|
$ 11.2M
|
|
PE Ratio
|
|
|
|
|
|
|
